🔬 The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors. Read more: targetedonc.com/view/rilvego… #BreastCancer #Oncology #CancerTreatment #ClinicalResearch

🔬 Early multidisciplinary survivorship care during radiotherapy boosts adherence and is associated with improved DFS in #HeadAndNeckCancer, with lower recurrence risk, according to a new analysis. Read more: targetedonc.com/view/early-s… #Oncology #CancerSurvivors #CancerCare

Can a personalized mRNA vaccine help prevent melanoma recurrence? 🧬 New findings on intismeran autogene plus pembrolizumab highlight the potential of individualized neoantigen therapy in high-risk #melanoma. Read more: targetedonc.com/view/persona… #ESMO26 #Oncology #SkinCancer

🫁 Without head-to-head data, how can clinicians determine which patients with advanced #NSCLC may be candidates for dual #immunotherapy? @MattGubensMD @UCSFCancer discusses key clinical and molecular characteristics that can help inform this choice.

🔎 FDA News: Following an end-of-phase 2 meeting with the #FDA, a phase 3 trial of oral RGT-61159 is planned in #AdenoidCysticCarcinoma in the first quarter of 2027. Read more: targetedonc.com/view/rgenta-… #CancerResearch #Oncology #ClinicalResearch #CancerTreatment #RareDiseases

💬 During a live event, Dr Robert Orlowski (@UTMDAnderson) and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple #myeloma. Read more: targetedonc.com/view/insuran… @Myeloma_Doc

Matthew Gubens, MD, MS (@UCSFCancer) explains how PD-L1 expression, disease burden, and co-mutations guide first-line immunotherapy selection in metastatic #NSCLC. 🎥 WATCH: targetedonc.com/view/how-to-… #LungCancer #Immunotherapy #Oncology #CancerTreatment | @MattGubensMD

🔎 FDA News: The #FDA has granted fast track designation to SBE303, an investigational Nectin-4–targeting ADC, for advanced #UrothelialCancer following enfortumab vedotin. Read more: targetedonc.com/view/fda-gra… #BladderCancer #GUOncology #CancerTreatment

Real-world evidence has shed new light on prostate cancer treatment strategies. Alicia Morgans, MD, MPH, @DanaFarber, discusses the real-world ARAAT trial and its key findings. targetedonc.com/authors/alic…

🔬 The ADC sofetabart mipitecan showed efficacy and safety in #OvarianCancer, leading to selection of a phase 3 dose for the FRAmework-01 trial. Read more: targetedonc.com/view/https:/… #GynOnc #Oncology #CancerTreatment #CancerResearch

🔎 FDA News: The #FDA has granted orphan drug designation to onvansertib for R/R #CMML, boosting development of the PLK1 inhibitor after early signals of activity. Read more: targetedonc.com/view/onvanse… #Leukemia #Hematology #Oncology #BloodCancer #CancerTreatment

🚨 Our coverage of #ESMO26 starts tomorrow! Visit hubs.li/Q04BT_HC0 for exclusive interviews and comprehensive coverage of the meeting's top news. 📰

🔬 Discharge doesn’t necessarily mean the end of toxicity management after lifileucel (Amtagvi) TIL therapy for advanced #melanoma. New findings in @JCO_ASCO highlight postdischarge AEs and the importance of continued monitoring. Read more: targetedonc.com/view/lifileu…

Something new is coming into focus. 👀 A fresh look. A new chapter. The same commitment to connecting science with everyday practice. Stay tuned. The reveal is coming soon. 🔜 #ComingSoon #Oncology

🩺 Practice Update: The @NCCN guidelines have incorporated cosibelimab (Unloxcyt) for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial. Read more: targetedonc.com/view/nccn-co… #CSCC #SkinCancer #Oncology #CancerCare

Morana Vojnic, MD, MBA (@RutgersCancer) discussed how FET-PET imaging, advanced molecular testing, and personalized treatment approaches are shaping the future of brain tumor care. 💬 Full interview: targetedonc.com/view/vojnic-… #NeuroOncology #PrecisionMedicine | @Moranaaa

🔬 A new analysis reveals major gaps in US #TNBC trial access, leaving rural and minority communities with fewer treatment options and research opportunities. Read more: targetedonc.com/view/triple-… #RuralHealth #CancerCare #ClinicalTrials #BreastCancer

Alicia Morgans, MD, MPH (@DanaFarber) discusses findings from ARAAT, a real-world analysis comparing darolutamide vs abiraterone when each is added to an ADT and docetaxel backbone in #mHSPC. 🎥 WATCH: targetedonc.com/view/dr-alic… #Oncology #ProstateCancer #RWD | @CaPsurvivorship

🔬 The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with #PolycythemiaVera receiving standard-of-care therapy. Read more: targetedonc.com/view/rusfert… #Hematology #ClinicalResearch

🔎 FDA News: MC001, an investigational chemoimmunotherapy ADC, has received #FDA fast track designation for #PancreaticCancer. Read more: targetedonc.com/view/mc001-r… #Oncology #CancerTreatment #GIOncology